CaptiGen Introduces Enhanced Covid-19 Testing

CaptiGen Introduces Enhanced Covid-19 Testing

CaptiGen was established under the leadership of Parvizi Surgical Innovation, an emerging healthcare company in Philadelphia, PA. PSI has more than 80 members, including world-renowned orthopedic surgeons, business leaders, clinicians, and scientists.

FREMONT, CA: CaptiGen, has announced the development of CaptiSwab, sterile, individually wrapped, knitted textile swabs for the collection of clinical samples for microbial detection through RT-PCR, standardculture, and next-generation sequencing (NGS).

Engineered to increase the yield of microbial genomic sampling, CaptiSwab features a double-layered, large, knitted fabric head designed to improve absorption and offer a better command of extraction from the device. CaptiSwab has been validated for SARS-CoV-2 detection via an approved RT-PCR assay and also has a proven lower Limit of Detection (LoD) compared to standard nasopharyngeal andoropharyngeal swabs on the market. CaptiSwabis validated to the M40-A2 standard for Quality Control of Microbiological Transport.

In addition to this, the CaptiGen Environmental Collection Kit was developed to support molecular diagnostic test systems. The self-contained kit was built to easily swab flat surfaces, high traffic, as well as high touch areas where pathogensandviruses can be detected. CaptiGen makes sure that costly cleaning protocols are measured for effectiveness and also to verify opportunities for improvement.

"Companies worldwide have implemented rigorous cleaning processes at great cost and with no standard for validation," stated Jaclyn Feula, VP, ME&T. "CaptiGen will allow users to promote and validate their cleaning process."

CaptiGen was established under the leadership of Parvizi Surgical Innovation, an emerging healthcare company in Philadelphia, PA. PSI has more than 80 members, including world-renowned orthopedic surgeons, business leaders,clinicians, and scientists.

"PSI is focused on improving the diagnosis, treatment, and prevention of infection. This focus is supported through a robust basic-science and clinical research initiative," stated Dr.JavadParvizi, CEO of PSI. "These clinical studies will help support the improvement of patient outcomes and surgical care."